Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCE
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
15 03 2022
15 03 2022
Historique:
received:
25
05
2021
accepted:
30
12
2021
pubmed:
28
1
2022
medline:
7
4
2022
entrez:
27
1
2022
Statut:
ppublish
Résumé
To evaluate costs and health-related quality of life (HRQoL) of neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). In this multicenter cross-sectional study, data on consumption of medical and nonmedical resources and work ability were assessed via patient questionnaires. Costs were analyzed in Euros for 2018 from the societal perspective. HRQoL was captured by the EuroQoL Group 5 Dimension 5 Level Scale (EQ-5D-5L) questionnaire. Clinical data were retrieved from the Neuromyelitis Optica Study Group (NEMOS) database. Two hundred twelve patients (80% women, median age 50 [19-83] years, median disease duration 7 [0-43] years, median Expanded Disability Status Scale [EDSS] score 3.5 [0-8.5], 66% aquaporin-4 immunoglobulin G [IgG] positive, 22% MOG IgG positive, 12% double seronegative) were analyzed. The mean total annual per capita cost of illness accounted for €59,574 (95% CI 51,225-68,293 or US dollars [USD] 70,297, 95% CI 60,445-80,586), and the mean index value of the EQ-5D-5L was 0.693 (95% CI 0.65-0.73). The most important cost drivers were informal care costs (28% of total costs), indirect costs (23%), and drugs (16%), especially immunotherapeutics. Costs showed a positive correlation with disease severity (ρ = 0.56, 95% CI 0.45-0.65); in the EDSS score 6.5 to 8.5 subgroup, the mean annual costs were €129,687 (95% CI 101,946-160,336 or USD 153,031, 95% CI 120,296-189,196). The HRQoL revealed a negative correlation to disease severity (ρ = -0.69, 95% CI -0.76 to -0.61); in the EDSS score 6.5 to 8.5 subgroup, the EQ-5D-5L mean index value was 0.195 (95% CI 0.13-0.28). Neither antibody status nor disease duration influenced the total annual costs or HRQoL. These German data from the era without approved preventive immunotherapies show enormous effects of the diseases on costs and quality of life. An early and cost-effective therapy should be provided to prevent long-term disability and to preserve quality of life.
Sections du résumé
BACKGROUND AND OBJECTIVES
To evaluate costs and health-related quality of life (HRQoL) of neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
METHODS
In this multicenter cross-sectional study, data on consumption of medical and nonmedical resources and work ability were assessed via patient questionnaires. Costs were analyzed in Euros for 2018 from the societal perspective. HRQoL was captured by the EuroQoL Group 5 Dimension 5 Level Scale (EQ-5D-5L) questionnaire. Clinical data were retrieved from the Neuromyelitis Optica Study Group (NEMOS) database.
RESULTS
Two hundred twelve patients (80% women, median age 50 [19-83] years, median disease duration 7 [0-43] years, median Expanded Disability Status Scale [EDSS] score 3.5 [0-8.5], 66% aquaporin-4 immunoglobulin G [IgG] positive, 22% MOG IgG positive, 12% double seronegative) were analyzed. The mean total annual per capita cost of illness accounted for €59,574 (95% CI 51,225-68,293 or US dollars [USD] 70,297, 95% CI 60,445-80,586), and the mean index value of the EQ-5D-5L was 0.693 (95% CI 0.65-0.73). The most important cost drivers were informal care costs (28% of total costs), indirect costs (23%), and drugs (16%), especially immunotherapeutics. Costs showed a positive correlation with disease severity (ρ = 0.56, 95% CI 0.45-0.65); in the EDSS score 6.5 to 8.5 subgroup, the mean annual costs were €129,687 (95% CI 101,946-160,336 or USD 153,031, 95% CI 120,296-189,196). The HRQoL revealed a negative correlation to disease severity (ρ = -0.69, 95% CI -0.76 to -0.61); in the EDSS score 6.5 to 8.5 subgroup, the EQ-5D-5L mean index value was 0.195 (95% CI 0.13-0.28). Neither antibody status nor disease duration influenced the total annual costs or HRQoL.
DISCUSSION
These German data from the era without approved preventive immunotherapies show enormous effects of the diseases on costs and quality of life. An early and cost-effective therapy should be provided to prevent long-term disability and to preserve quality of life.
Identifiants
pubmed: 35082170
pii: WNL.0000000000200052
doi: 10.1212/WNL.0000000000200052
pmc: PMC8935443
doi:
Substances chimiques
Aquaporin 4
0
Autoantibodies
0
Myelin-Oligodendrocyte Glycoprotein
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1184-e1196Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504
pubmed: 30345331
Orphanet J Rare Dis. 2014 Dec 18;9:210
pubmed: 25519771
J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):1005-15
pubmed: 27113605
J Health Serv Res Policy. 2004 Oct;9(4):197-204
pubmed: 15509405
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Neurol Neuroimmunol Neuroinflamm. 2020 Feb 5;7(2):
pubmed: 32024795
JAMA Oncol. 2016 Jan;2(1):19-21
pubmed: 26501848
Pharmacoeconomics. 2018 Jun;36(6):663-674
pubmed: 29460066
J Neuroinflammation. 2012 Jan 19;9:14
pubmed: 22260418
J Neuroinflammation. 2018 May 3;15(1):134
pubmed: 29724224
Expert Opin Biol Ther. 2020 Sep;20(9):1061-1072
pubmed: 32228250
N Engl J Med. 2019 Aug 15;381(7):614-625
pubmed: 31050279
Pharmacoeconomics. 1998 May;13(5 Pt 2):607-22
pubmed: 17165327
Mult Scler. 2017 Aug;23(2_suppl):78-90
pubmed: 28643593
Neurol Neuroimmunol Neuroinflamm. 2019 Jun 20;6(4):e580
pubmed: 31355316
Mult Scler Relat Disord. 2017 Jan;11:45-50
pubmed: 28104256
Gesundheitswesen. 2010 Dec;72(12):917-33
pubmed: 20865653
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Nat Rev Dis Primers. 2020 Oct 22;6(1):85
pubmed: 33093467
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Lancet. 2019 Oct 12;394(10206):1352-1363
pubmed: 31495497
N Engl J Med. 2019 Nov 28;381(22):2114-2124
pubmed: 31774956
Ann Neurol. 2016 Feb;79(2):206-16
pubmed: 26537743
J Neurol. 2014 Jan;261(1):1-16
pubmed: 24272588
Pharmacoeconomics. 2019 May;37(5):631-643
pubmed: 30746613
Eur J Neurol. 2011 Jun;18(6):836-41
pubmed: 21087360
Eur J Health Econ. 2019 Aug;20(6):933-944
pubmed: 31030292
Clin Mol Hepatol. 2014 Dec;20(4):327-37
pubmed: 25548737
Gesundheitswesen. 2015 Jan;77(1):53-61
pubmed: 25025287
Int J MS Care. 2019 May-Jun;21(3):129-134
pubmed: 31191178
Eur J Health Econ. 2006 Sep;7 Suppl 2:S34-44
pubmed: 17310337
Lancet Neurol. 2020 May;19(5):402-412
pubmed: 32333898
J Neuroinflammation. 2016 Sep 27;13(1):280
pubmed: 27793206
Mult Scler Relat Disord. 2017 Oct;17:116-122
pubmed: 29055439
J Neurol Neurosurg Psychiatry. 2000 Feb;68(2):144-9
pubmed: 10644777